Guggenheim Reiterates Neutral Rating for Sionna Therapeutics (NASDAQ:SION)

Key Points

• Guggenheim reiterated its “neutral” rating on Sionna Therapeutics, while several other analysts also downgraded or maintained cautious ratings. The stock has an average consensus rating of “Hold,” although reported price targets vary widely.
• Sionna shares fell sharply to $4.58 amid a major clinical setback, after the company discontinued the SION-719 cystic fibrosis program and refocused its pipeline on remaining development programs.
• The company reported a quarterly loss of $0.66 per share, slightly worse than the $0.64 consensus estimate, while insiders sold roughly 403,726 shares worth $18.3 million over the past three months.

Sionna Therapeutics (NASDAQ:SION - Get Free Report)'s stock had its "neutral" rating reiterated by research analysts at Guggenheim in a report released on Monday, MarketBeat.com reports.

Other equities analysts have also issued reports about the stock. Raymond James Financial lowered shares of Sionna Therapeutics from a "strong-buy" rating to a "market perform" rating in a report on Monday. Wedbush reissued a "neutral" rating and set a $5.00 price target on shares of Sionna Therapeutics in a research report on Monday. Citizens Jmp downgraded shares of Sionna Therapeutics from a "mkt outperform" rating to a "market perform" rating in a research report on Monday. Royal Bank Of Canada raised shares of Sionna Therapeutics from an "underperform" rating to a "sector perform" rating and set a $5.00 target price for the company in a research report on Monday. Finally, Stifel Nicolaus reaffirmed a "hold" rating and issued a $7.00 price target on shares of Sionna Therapeutics in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $42.22.

Sionna Therapeutics Stock Performance

SION stock traded down $46.46 on Monday, reaching $4.58. The company's stock had a trading volume of 27,678,474 shares, compared to its average volume of 581,212. The firm has a market cap of $206.88 million, a PE ratio of -2.06 and a beta of 1.32. The business has a fifty day simple moving average of $42.35 and a two-hundred day simple moving average of $40.42. Sionna Therapeutics has a 12-month low of $4.01 and a 12-month high of $54.97.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.02). As a group, research analysts anticipate that Sionna Therapeutics will post -2.63 earnings per share for the current fiscal year.

Insider Buying and Selling at Sionna Therapeutics

In related news, Director Peter A. Thompson sold 115,844 shares of the firm's stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total value of $5,270,902.00. Following the completion of the transaction, the director owned 2,555,877 shares in the company, valued at $116,292,403.50. This trade represents a 4.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the business's stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00. Following the sale, the director owned 2,555,877 shares in the company, valued at approximately $116,292,403.50. The trade was a 4.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 403,726 shares of company stock worth $18,259,354. 5.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SION. Deutsche Bank AG grew its position in Sionna Therapeutics by 4.5% during the fourth quarter. Deutsche Bank AG now owns 10,029 shares of the company's stock valued at $413,000 after buying an additional 433 shares during the period. Bank of America Corp DE grew its holdings in Sionna Therapeutics by 8.8% in the third quarter. Bank of America Corp DE now owns 6,541 shares of the company's stock valued at $192,000 after purchasing an additional 529 shares during the period. MetLife Investment Management LLC raised its stake in shares of Sionna Therapeutics by 6.6% during the 4th quarter. MetLife Investment Management LLC now owns 8,565 shares of the company's stock worth $352,000 after buying an additional 532 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Sionna Therapeutics by 35.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company's stock valued at $70,000 after buying an additional 619 shares in the last quarter. Finally, State of Wyoming acquired a new stake in shares of Sionna Therapeutics in the second quarter valued at about $35,000.

More Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Stifel Nicolaus reaffirmed its “hold” rating and set a $7.00 price target, indicating potential upside from the current trading level. However, the unchanged cautious rating suggests the analyst remains concerned about the company’s development risks. Stifel Nicolaus rating update
• Neutral Sentiment: Sionna reported topline results from two cystic fibrosis development programs and said it plans to refocus its pipeline following the clinical setback. The remaining programs could become more important to the company’s valuation, but their prospects remain dependent on future data. Sionna topline data and corporate update
• Negative Sentiment: The company discontinued SION-719 after its mid-stage cystic fibrosis trial failed to produce sufficiently compelling results. Investors viewed the decision as a major setback because it removes a key clinical asset and increases reliance on earlier-stage programs. Sionna cystic fibrosis trial results
• Negative Sentiment: A shareholder-rights law firm announced an investigation into whether Sionna or its executives violated federal securities laws in connection with disclosures about the trial results. The investigation adds legal and reputational risk, although no wrongdoing has been established. Johnson Fistel investigation

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source